argenx SE (NASDAQ:ARGX) Holdings Lowered by Harvey Capital Management Inc.

Harvey Capital Management Inc. lessened its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 18.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,561 shares of the company's stock after selling 2,533 shares during the quarter. argenx accounts for 1.7% of Harvey Capital Management Inc.'s investment portfolio, making the stock its 21st biggest position. Harvey Capital Management Inc.'s holdings in argenx were worth $7,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of ARGX. Stifel Financial Corp grew its holdings in argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock worth $4,788,000 after acquiring an additional 1,170 shares in the last quarter. FMR LLC grew its holdings in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Simplify Asset Management Inc. grew its holdings in argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock worth $1,311,000 after acquiring an additional 944 shares in the last quarter. Ritholtz Wealth Management grew its holdings in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in argenx during the 3rd quarter worth $571,000. Institutional investors and hedge funds own 60.32% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ARGX. JMP Securities raised their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. HC Wainwright reissued a "buy" rating and set a $717.00 price objective (up from $670.00) on shares of argenx in a report on Tuesday, January 14th. Oppenheimer reaffirmed an "outperform" rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a report on Friday, November 1st. Finally, Baird R W lowered shares of argenx from a "strong-buy" rating to a "hold" rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, argenx presently has a consensus rating of "Moderate Buy" and a consensus price target of $658.39.

argenx Trading Down 1.8 %

NASDAQ:ARGX traded down $11.93 during mid-day trading on Friday, hitting $639.41. The stock had a trading volume of 266,806 shares, compared to its average volume of 282,116. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21. The stock has a market capitalization of $38.85 billion, a price-to-earnings ratio of -726.60 and a beta of 0.58. The company has a 50 day simple moving average of $639.59 and a 200-day simple moving average of $581.81.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.